Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Evoke KYNE promotes Carolyn Coyle to executive vice president

Previously, Coyle also worked as senior vice president in the healthcare practice at Ruder Finn

- PMLiVE

McCann Health New York promotes Matt Silver to the new role of president

Silver first joined McCann Health New York in 2017 as executive vice president and managing director

- PMLiVE

PureTech adds potential IBD therapeutic to pipeline after buying out Alivio Therapeutics

Alivio is developing therapeutic candidates for a number of inflammatory disorders

Biogen Idec building

Biogen discontinues clinical development of anti-tau antibody for Alzheimer’s disease

The drug failed to meet the primary efficacy endpoint in a phase 2 study

- PMLiVE

Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy

Vaccine candidate failed to meet prespecified measure of statistical success in clinical trial

- PMLiVE

Patient diversity in clinical trials needs to be centre stage

By Danny Buckland

- PMLiVE

Ashfield Advisory adds Mary-Kate McGarry and Emer Jameson to senior leadership team

McGarry has been appointed as vice president of strategy, while Jameson joins as vice president of HR

- PMLiVE

Servier, Oncodesign select first preclinical candidate from Parkinson’s disease collaboration

Oncodesign received the first milestone payment in February 2020 as part of the collaboration

- PMLiVE

GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug

British drug-maker will pay $625m upfront for access to iTeos' anti-TIGIT monoclonal antibody

- PMLiVE

Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses

Pfizer/BioNTech and AZ vaccines found to be 96% and 92% effective against variant, respectively

- PMLiVE

Regeneron’s COVID-19 drug boosts survival in hospitalised patients lacking antibodies

REGEN-COV reduced the risk of death among patients who did not have a natural antibody response

Your clinical trial participants are precious, so treat them as such

By Su Smith

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links